This is supported by a recent series of seven patients with lymphoma who after initially having PD after CD19 CAR T cell therapy, went on to receive salvage IBR followed by reinfusion of CD19 CAR T cells, with all patients achieving a response, including six who achieved a CR [44]. This evidence concerns the gene CD19 and lymphoma.